Page last updated: 2024-11-13

fortimicin a sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fortimicin A: RN given refers to parent cpd; Abbott-44747 is for disulfate; see also records for fortimicin B & fortimicins; structure in 8th source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72734319
CHEMBL ID3989466
CHEBI ID31242
MeSH IDM0080600

Synonyms (30)

Synonym
fortimicin a
abbott-44747
astromicin sulfate
l-chiro-inositol, 4-amino-1-((aminoacetyl)methylamino)-1,4-dideoxy-3-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-l-lyxo-heptopyranosyl)-6-o-methyl-, disulfate
4-amino-1-(2-amino-n-methylacetamido)-1,4-dideoxy-3-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-l-lyxo-heptopyranosyl)-6-o-methyl-l-chiro-inositol sulfate (1:2) (salt)
fortimicin a sulfate
abbott 44747
l-chiro-inositol, 4-amino-1-((aminoacetyl)methylamino)-1,4-dideoxy-3-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-l-lyxo-heptopyranosyl)-6-o-methylsulfate (1:2) (salt)
xk 70-1 sulfate
kw-1070 sulfate
astromicin sulfate [usan:jan]
astromicin sulfate (jan/usan)
fortimicin (tn)
D01881
unii-poy3s0t3bd
poy3s0t3bd ,
astromicin sulfate [jan]
astromicin sulfate [usan]
l-chiro-inositol, 4-amino-1-((aminoacetyl)methylamino)-1,4-dideoxy-3-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-.beta.-l-lyxo-heptopyranosyl)-6-o-methylsulphate (1:2) (salt)
4-amino-1-(2-amino-n-methylacetamido)-1,4-dideoxy-3-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-.beta.-l-lyxo-heptopyranosyl)-6-o-methyl-l-chiro-inositol sulphate (1:2) (salt)
astromicin sulphate
astromicin sulfate [who-dd]
fortimicin a sulphate
4-amino-1-(2-amino-n-methylacetamido)-1,4-dideoxy-3-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-.beta.-l-lyxo-heptopyranosyl)-6-o-methyl-l-chiro-inositol sulfate (1:2) (salt)
astromicin sulfate [mart.]
l-chiro-inositol, 4-amino-1-((aminoacetyl)methylamino)-1,4-dideoxy-3-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-.beta.-l-lyxo-heptopyranosyl)-6-o-methylsulfate (1:2) (salt)
astromycin sulfate
CHEBI:31242
CHEMBL3989466
Q27286677

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters were calculated using one-compartment open model (i."( [The pharmacokinetic studies on astromicin in dogs. Intramuscular, intravenous or drip intravenous administration].
Deguchi, T; Inoue, A; Kobayashi, S, 1986
)
0.27
" The peak concentration was achieved at the end of infusion and was dose-related."( [Pharmacokinetic studies of astromicin using a constant-rate continuous intravenous infusion method].
Inoue, A; Kobayashi, S; Yamasaku, F, 1986
)
0.27
" Concentrations of ASTM in blood were determined for pharmacokinetic analysis."( [Pharmacokinetics of astromicin intravenous drip infusion in patients with renal disorders].
Inoue, A; Kobayashi, S; Moriguchi, R; Naide, Y; Nemoto, S; Suzuki, K; Yamagoshi, T, 1986
)
0.27
" The pharmacokinetic studies of ASTM were carried out using one-compartment open model (i."( [The pharmacokinetic studies on astromicin in rats. Intramuscular, intravenous or drip intravenous administration].
Inoue, A; Kobayashi, H; Kurimoto, T; Okachi, R, 1984
)
0.27

Dosage Studied

ExcerptRelevanceReference
" These sensitivities seem good enough for a clinical application of the method considering usual dosage levels of the drugs."( [High performance liquid chromatographic determination of astromicin and cefsulodin used in combination in blood samples].
Inoue, A; Kobayashi, S; Takai, K, 1986
)
0.27
" These sensitivities seem good enough for a clinical application of the method considering usual dosage levels of the drugs."( [High performance liquid chromatographic determination of astromicin and cefoperazone used in combination in blood samples].
Inoue, A; Kobayashi, S; Masuda, S; Takai, K, 1986
)
0.27
" These sensitivities seem good enough for a clinical application of the method considering usual dosage levels of these drugs."( [High performance liquid chromatographic determination of astromicin and piperacillin used in combination in blood samples].
Inoue, A; Kobayashi, S; Masuda, S; Takai, K, 1986
)
0.27
" In these experiment, ASTM which is lower in toxicity than AMK did not approach 35 micrograms/ml even at the peak level with the dosage of 400 mg in 1 hour."( [Pharmacokinetic studies of astromicin using a constant-rate continuous intravenous infusion method].
Inoue, A; Kobayashi, S; Yamasaku, F, 1986
)
0.27
" Cumulative drug dose-response curves were obtained for three different muscles in 24 rabbits."( Neuromuscular blocking effects of the aminoglycoside antibiotics arbekacin, astromicin, isepamicin and netilmicin on the diaphragm and limb muscles in the rabbit.
Hashimoto, Y; Kato, M; Liu, M, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminoglycoside sulfate salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (75.00)18.7374
1990's14 (21.88)18.2507
2000's1 (1.56)29.6817
2010's1 (1.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.98 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.13%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]